CTOs on the Move

Synthorx

www.synthorx.com

 
Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx`s expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.synthorx.com
  • 11099 North Torrey Pines Road Suite 290
    La Jolla, CA USA 92037
  • Phone: 858.750.4700

Executives

Name Title Contact Details

Funding

Synthorx raised $63M on 04/30/2018

Similar Companies

Dalton Pharma Services

Dalton Pharma Services is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jubilant Clinsys

Clinsys practices this philosophy with its clients. We focus on building long-term relationships and successful partnerships with our pharmaceutical and biotech partners through a total dedication to delivering on commitments, understanding client needs

Fraunhofer Center for Laser Technology

Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GenSight Biologics

GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics` pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics` lead product candidate, GS010, is in Phase III trials in Leber`s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics` product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.

Epigentek

Epigentek is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.